x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

This Is Why with Dr. Busti

Anthony Busti, MD, PharmD, MSc, FNLA, FAHA

This Is Why exists to help medical professionals understand the why behind the decisions they make every day in patient care. Our approach is about integrating evidence, clinical relevance and real-world application so that what your learn connects directly with the patients you serve.

education medicine

All Episodes

25:52

LAMA (Long-Acting Muscarinic Antagonists)...

This Is Why with Dr. Busti ·

2026/01/27

In this lecture from This is Why, Dr. Busti will explain the COPD maintenance inhalers you’ll actually see in practice. In this pharmacology review, we break down LAMA (long-acting muscarinic antagonist) bronchodilators—one of the most important bronchodilator classes for COPD treatment—so you can confidently understand the drugs, the mechanism, and the real-world clinical use. You’ll learn how to: What LAMA / antimuscarinic bronchodilators are and how they workWhere LAMA inhalers fit in COPD...

en-us

23:48

SAMA (Short-Acting Muscarinic Antagonists)...

This Is Why with Dr. Busti ·

2026/01/27

Short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care. In this lecture from This is Why, Dr. Busti will learn about short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care—and on exams like the NCLEX. In this lecture, you’ll learn exactly how SAMAs work, when to use them, and what safety pearls can help you avoid common clinical pitfalls in COPD. You’ll learn how to: Mecha...

en-us

35:14

SGLT2 Inhibitors (eg, Empagliflozin) for Diabetes:...

This Is Why with Dr. Busti ·

2026/01/27

SGLT2 inhibitors (bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) don’t just lower glucose and A1C, but these meds have become relevant in cardiovascular disease and chronic kidney disease in the right patients also with type 2 diabetes (T2DM). In this lecture from This is Why, Dr. Busti will make the SGLT2 inhibitors make sense as they provide cardiorenal protection above their improvements in A1C. You’ll learn how to: - Mechanism of action (MOA): how SGLT2 block...

en-us

38:43

SABA (Short-Acting Beta Agonists) Bronchodilators for...

This Is Why with Dr. Busti ·

2026/01/27

In this lecture from This is Why, Dr. Busti will break down SABA (Short-Acting Beta Agonist) bronchodilators, like albuterol, for the acute management of asthma symptoms and COPD flare-ups. You’ll learn how to: - What SABAs are and when they’re used (rescue vs controller) - Beta-2 agonist mechanism of action (bronchodilation and smooth muscle effects) - How fast albuterol works, typical duration, and why it’s “short-acting” - Core therapeutic uses in asthma and COPD - How SABAs fit into tre...

en-us

21:43

Sulfonylureas (Glyburide, Glipizide): Type 2 Diabetes...

This Is Why with Dr. Busti ·

2026/01/27

Dr. Busti covers one of the most-tested Type 2 diabetes drug classes—sulfonylureas. If you’ve ever mixed up glyburide vs glipizide, worried about hypoglycemia, or wanted a clear “when do I pick this?” framework, this drug class review is for you. In this lecture from This is Why, Dr. Busti will break down Sulfonylureas (Glyburide, Glipizide) step-by-step so you can confidently in the context of treating type 2 diabetes (T2DM). You’ll learn how to: - Mechanism of action: how sulfonylureas in...

en-us

36:18

LABA (Long-Acting Beta Agonists) Bronchodilators for...

This Is Why with Dr. Busti ·

2026/01/27

In this lecture from This is Why, Dr. Busti will explain how Long-Acting Beta Agonists (LABAs) work, where they fit in therapy for the management of asthma and COPD. You’ll learn how to: - Mechanism of action: beta-2 receptor activation → bronchodilation (airway smooth muscle relaxation) - Clinical use: LABAs in COPD maintenance vs asthma (must be combined with ICS) - Onset/duration differences and practical inhaler considerations - Adverse effects & warnings: tachycardia, tremor, hypok...

en-us

60:32

Insulin Types: Rapid, NPH, Basal for Diabetes -...

This Is Why with Dr. Busti ·

2026/01/27

Insulin doesn’t have to be confusing when learning how to treat Type 1 and Type 2 diabetes mellitus. In this lecture from This is Why, Dr. Busti will explain how to quickly recognize insulin types, predict onset/peak/duration, and apply basal–bolus dosing concepts to real-world Type 1 and Type 2 diabetes care. You’ll learn how to: - How to identify rapid-, short-, intermediate-, and long-acting insulin for Diabetes - The difference between basal insulin vs bolus (mealtime) insulin - How bas...

en-us

12:57

Meglitinides (Nateglinide & Repaglinide): Diabetes...

This Is Why with Dr. Busti ·

2026/01/27

Meglitinides (Nateglinide & Repaglinide) can feel like the “forgotten” oral diabetes drugs—but they show up on exams, in real-world medication histories, and in questions about postprandial glucose control and hypoglycemia and weight gain risk. In this lecture from This is Why, Dr. Busti will explain the meglitinides in a clear, clinically relevant way so you can recognize them quickly and use the concepts confidently in the context of Type 2 diabetes (T2DM). You’ll learn how to: - Megl...

en-us

46:25

GLP-1 Receptor Agonists (eg, Semaglutide) Diabetes...

This Is Why with Dr. Busti ·

2026/01/27

Understand the GLP-1 receptor agonists—and why agents like semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide, dulaglutide, and exenatide have become one of the most talked-about type 2 diabetes medications in modern practice. In this lecture from This is Why, Dr. Busti will break GLP-1s down in a clear, clinically relevant way so you can confidently explain how they work, when to use them, and what to watch for clinically when managing patients with type 2 diabetes and/or obesity. You’ll l...

en-us

15:53

TZDs (Pioglitazone) for Type 2 Diabetes: Pharmacology...

This Is Why with Dr. Busti ·

2026/01/27

In this lecture from This is Why, Dr. Busti will break down pioglitazone and the thiazolidinediones (TZDs) so you can confidently explain the mechanism, clinical use, side effects, and key contraindications for type 2 diabetes (T2DM). You’ll learn how to: - TZDs (pioglitazone): where they fit in type 2 diabetes (T2DM) therapy - Mechanism of action: PPAR-γ agonist → increased insulin sensitivity (muscle/adipose) and improved glucose utilization - Expected impact on A1C reduction and how long...

en-us

21:00

Alpha-Glucosidase Inhibitors for Diabetes:...

This Is Why with Dr. Busti ·

2026/01/26

In this lecture from This is Why, Dr. Busti will teach you about Alpha-Glucosidase Inhibitors for Diabetes — the pharmacology made easy breakdown of acarbose and miglitol for type 2 diabetes. You’ll learn how to: - Explain how alpha-glucosidase inhibitors reduce postprandial hyperglycemia - Identify where these drugs work (GI tract) and why they don’t cause hypoglycemia by themselves - Compare acarbose vs miglitol (what’s similar, what’s different) - Recognize common GI adverse effects (e.g....

en-us

23:09

Amylin Analogs (Pramlintide) for Diabetes:...

This Is Why with Dr. Busti ·

2026/01/26

Amylin Analogs (Pramlintide) for Diabetes: Pharmacology Made Easy. In this lecture from This is Why, Dr. Busti will explain how pramlintide (Symlin/SymlinPen) works and when it’s used as an adjunct to insulin for type 1 diabetes (and select type 2 diabetes cases). In this diabetes pharmacology review, I break down the mechanism of action of an amylin analog, why it helps postprandial glucose control, and the key clinical pearls you need for exams and practice. You’ll learn how to: - Wh...

en-us

31:45

Metformin - A Biguanide for Type 2 Diabetes:...

This Is Why with Dr. Busti ·

2026/01/26

Metformin is a first-line oral medication for type 2 diabetes. In this lecture from This is Why, Dr. Busti will explain how metformin works to lower the A1c and help patients with type 2 diabetes get to their A1C goals. You’ll learn how to: - Metformin mechanism of action (MOA): how biguanides lower glucose and improve insulin resistance - Where metformin fits in type 2 diabetes therapy (first-line option and combination use) - Key clinical benefits (A1C lowering, weight neutrali...

en-us

21:29

DPP-4 Inhibitors for Type 2 Diabetes: Pharmacology...

This Is Why with Dr. Busti ·

2026/01/26

In this lecture from This is Why, Dr. Busti will learn about the application of DPP-4 inhibitors in the management of type 2 diabetes mellitus (T2DM). The DPP-4 inhibitors (e.g., sitagliptin, linagliptin, saxagliptin) have an impact of incretins (GIP, GLP-1) which have continued to evolve in other treatment options. You’ll learn how to: - Mechanism of action: DPP-4 inhibition and impact on incretins (GLP-1/GIP) - Key drugs: Sitagliptin, linagliptin, saxagliptin - Clinical role: where D...

en-us

31:29

Tirzepatide (GIP/GLP-1 Agonists) for Diabetes:...

This Is Why with Dr. Busti ·

2026/01/26

Tirzepatide (Mounjaro/Zepbound)—the dual incretin GIP/GLP-1 agonist—is a beneficial treatment of type 2 diabetes and/or obesity. In this lecture from This is Why, Dr. Busti will break down how tirzepatide works (MOA), why combining GIP + GLP-1 improves A1C reduction and supports weight loss, and where it fits in the treatment of type 2 diabetes. You’ll also get the high-yield points you need for exams and the bedside: tirzepatide dosing basics, common adverse effects, contraindications/...

en-us

63:25

Statins (HMG-CoA Reductase Inhibitors): LDL Lowering...

This Is Why with Dr. Busti ·

2026/01/20

Statins (HMG-CoA Reductase Inhibitors) are the foundation of LDL lowering and ASCVD prevention. In this lecture from This is Why, Dr. Busti will make statin pharmacology easy to understand, but also clinically relevant in the proper context of the evidence. The use of HMG CoA reductase inhibitors: atorvastatin, rosuvastatin, simvastatin, pitavastatin, and pravastatin are drugs in this drug class that Dr. Busti will review. You’ll learn how to: MOA: How HMG-CoA reductase inhibitors reduc...

en-us

26:43

Omega-3 Fatty Acids (DHA, EPA): Pharmacology Made Easy

This Is Why with Dr. Busti ·

2026/01/20

Omega-3 fatty acids made easy: learn EPA vs DHA, how fish oil works, and when to use icosapent ethyl (Vascepa) in real clinical practice. In this lecture from This is Why, Dr. Busti connects PUFAs (polyunsaturated fatty acids) to outcomes, focusing on triglyceride lowering, cardiovascular risk reduction, and the key differences between OTC fish oil supplements and prescription EPA. You’ll learn how to: What omega-3 fatty acids (EPA & DHA) are and how they workFish oil (EPA vs DHA): what m...

en-us

29:38

Fibrates (Fenofibrate & Gemfibrozil) for TG:...

This Is Why with Dr. Busti ·

2026/01/20

Learn fibrates (fibric acid derivatives)—fenofibrate and gemfibrozil—common triglyceride-lowering drugs for hypertriglyceridemia. In this lecture from This is Why, Dr. Busti will break down how fibrates (fenofibrate and gemfibrozil) work, when to use them, and the safety pearls you need for the patient with high triglycerides, which can lead to pancreatitis. You’ll learn how to: - Mechanism: PPAR-α activation → ↓ triglycerides (TG), ↓ VLDL, ↑ HDL - Fenofibrate vs gemfibrozil: key differences...

en-us

33:08

Ezetimibe (Cholesterol Absorption Inhibitors):...

This Is Why with Dr. Busti ·

2026/01/20

In this lecture from This is Why, Dr. Busti will break down Ezetimibe (Zetia)—the classic cholesterol absorption inhibitor—and make the pharmacology easy, high-yield, and clinically relevant. You’ll learn how ezetimibe lowers LDL-C, where it fits in dyslipidemia/hyperlipidemia therapy, and how it’s commonly used as add-on therapy to statins. You’ll learn how to: - Mechanism of action: how the cholesterol absorption inhibitor, ezetimibe, works to lower LDL cholesterol - Clinical use: when to ...

en-us

29:32

ATP Citrate Lyase (ACL) Inhibitors: Bempedoic Acid...

This Is Why with Dr. Busti ·

2026/01/20

ATP Citrate Lyase (ACL) Inhibitors made simple. In this lecture from This is Why, Dr. Busti will provide you with a review of Bempedoic Acid (Nexletol), and you’ll learn how this lipid-lowering drug works, when to use it (including statin intolerance), and the key clinical pearls you need for exams and practice. You’ll learn how to: - What ATP citrate lyase inhibitors are and where they work in cholesterol synthesis - Bempedoic acid mechanism of action + why it’s different from statins...

en-us

77 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College